The 15th Conference on Retroviruses and Opportunistic Infections

Key Links:

By Topic:

Search:

The 15th Conference on Retroviruses and Opportunistic Infections

BOSTON, MASSACHUSETTS
FEBRUARY 3-6, 2008

Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds
One of the most talked-about studies presented at CROI 2008, the new D:A:D findings focus on the impact of specific antiretrovirals on heart attack risk in HIV-infected patients. Jens Lundgren, M.D., Chief Physician and Director of the Copenhagen HIV Programme, summarizes the data and discusses the ramifications of the results.

Read Transcript Listen (30 min.) More Research

HIV Treatment/Complications		HIV/Hepatitis Coinfection

CCR5 Inhibitors in Development: New Data on SCH532706 and Vicriviroc Sarah Pett, M.D., of the University of South Wales in Australia, reviews phase 1 trial results on SCH532706; Barry Zingman, M.D., of Montefiore Medical Center in New York, discusses 48-week results from a study on vicriviroc. More Highlights: Resuming Treatment Partly Restores Health of Patients in SMART Study Mario Stevenson, Ph.D., Discusses Targets for a New Generation of HIV Antiretrovirals More Research		Immune Reconstitution May Trigger Hepatic Flares in HIV/Hepatitis B Coinfected Patients Starting HAART Megan Crane, of Monash University in Melbourne, Australia, explores the immunopathogenesis of hepatic flares following the initiation of HAART with anti-hepatitis B activity in patients who are coinfected with HIV and hepatitis B. More Highlights: Rapid Liver Fibrosis Occurring More Frequently Among HIV-Infected Men Newly Coinfected With Hepatitis C More Research
Developing World		HIV Prevention

HAART Use Enlivens Sex Lives of Rural Ugandans, But Does Not Increase Risky Behavior, Study Says Rebecca Bunnell, Sc.D., discusses the impact of antiretroviral use on the sexual behavior and HIV risk activities of HIV-infected people in rural Uganda. More Highlights: HIV Prevention Evolves in Developing World More Research		Surprisingly, Acyclovir for HSV-2 Treatment Fails to Curtail HIV Acquisition Connie Celum, M.D., discusses unexpectedly disappointing results from a study examining whether the use of acyclovir to treat herpes simplex virus type-2 infection can, in turn, help reduce a person's risk of HIV acquisition. More Highlights: Presence of Lactobacillus May Reduce HIV Concentration in Vaginal Fluid More Research

About This Conference

The Body's coverage of the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008) will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on CROI 2008, please visit the conference's Web site. You may also view the conference program online.

Funding for coverage of this conference is provided, in part, by Abbott Laboratories.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.